BRIEF-Sarepta Therapeutics says muscle drug meets main goal of mid-stage study

Oct 3 (Reuters) - Sarepta Therapeutics Inc :

* Announces eteplirsen meets primary endpoint of increased novel dystrophin and

achieves significant clinical benefit on 6-minute walk test after 48 weeks of

treatment in phase iib study in duchenne muscular dystrophy

* Safety profile of eteplirsen was evaluated and there were no

treatment-related adverse events, no serious adverse events

((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))

((For more news, please click here ))